Published on 3 Oct 2022 on Benzinga via Yahoo Finance

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

Novo Nordisk A/S (NYSE: NVO) has completed posting topline results across its six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in people with diabetes.In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study.Novo’s icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily control. The study comprised 1,085 insulin-naive people with type 2 diabetes. Patients on icodec also used an app to guide their dosing.The news adds to ONWARDS trial readouts dating back to April.In July, the company announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec.Earlier this month, Novo picked up worldwide marketing rights to Zealand Pharma A/S’s (NASDAQ: ZEAL) diabetes treatment Zegalogue and inked a $1.1 billion buyout of Forma Therapeutics Holdings Inc (NASDAQ: FMTX) for its sickle cell drug.Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the U.S., the EU, and China in 1H of 2023.Price Action: NVO shares are up 2.26% at $101.88 on the last check Monday.

See more from Benzinga